{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:13:28Z","timestamp":1774534408366,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.therap.2018.07.001","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T12:51:52Z","timestamp":1530967912000},"page":"511-520","source":"Crossref","is-referenced-by-count":9,"title":["Int\u00e9r\u00eat de la mise \u00e0 disposition de la naloxone aupr\u00e8s des usagers de drogues pour le traitement d\u2019urgence de surdosage d\u2019opio\u00efdes"],"prefix":"10.1016","volume":"73","author":[{"given":"Elisabeth","family":"Frauger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-5556","authenticated-orcid":false,"given":"Farid","family":"Kheloufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9851-0233","authenticated-orcid":false,"given":"Quentin","family":"Boucherie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Monzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Jupin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.therap.2018.07.001_bib0335","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2515\/therapie\/2011037","article-title":"Evolution of opioids reimbursement since 2004\u00a0from the National Database of the General Health Insurance System","volume":"66","author":"Pauly","year":"2011","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.therap.2018.07.001_bib0340","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2515\/therapie\/2014235","article-title":"New synthetic drugs in addictovigilance","volume":"70","author":"Chavant","year":"2015","journal-title":"Therapie"},{"issue":"1","key":"10.1016\/j.therap.2018.07.001_bib0345","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/15563650.2016.1209764","article-title":"Near death from a novel synthetic opioid labeled U-47700: emergence of a new opioid class","volume":"55","author":"Schneir","year":"2017","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.therap.2018.07.001_bib0350","series-title":"Office des Nations unies contre la drogue et le crime. Global s mart update: fentanyl and its analogues \u2013\u00a050\u00a0years on","author":"ONUDC","year":"2017"},{"key":"10.1016\/j.therap.2018.07.001_bib0355","series-title":"Enqu\u00eate d\u2019addictovigilance sur les d\u00e9riv\u00e9s di fentanyl ou \u00ab\u00a0fentanyloides\u00a0\u00bb","author":"ANSM","year":"2017"},{"key":"10.1016\/j.therap.2018.07.001_bib0360","series-title":"Information relative \u00e0 l\u2019identification de fentanyl et de fentanylo\u00efdes dans des poudres pr\u00e9sent\u00e9es comme de l\u2019h\u00e9ro\u00efne","author":"ARS","year":"2016"},{"key":"10.1016\/j.therap.2018.07.001_bib0365","series-title":"Information-alerte relative \u00e0 l\u2019identification de substances fentanylo\u00efdes et risque pour les usagers","author":"ARS Corse","year":"2017"},{"issue":"4","key":"10.1016\/j.therap.2018.07.001_bib0370","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2017.01.010","article-title":"Surveillance system on drug abuse: interest of the French national OPPIDUM program of French addictovigilance network","volume":"72","author":"Frauger","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.07.001_bib0375","series-title":"Organisation mondiale de la sant\u00e9 2014. Community management of opioid overdose","author":"OMS","year":"2014"},{"issue":"3","key":"10.1016\/j.therap.2018.07.001_bib0380","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.therap.2018.07.001_bib0385","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/clpt.2010.154","article-title":"Prescription drug abuse: insight into the epidemic","volume":"88","author":"Hernandez","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2018.07.001_bib0390","series-title":"Substance abuse and mental health services administration-key substance use and mental health indicators in the United States: results from the 2015\u00a0national survey on drug use and health","author":"SAMSHA","year":"2015"},{"issue":"4\u00a0Pt 1","key":"10.1016\/j.therap.2018.07.001_bib0395","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.lpm.2016.02.014","article-title":"Use of strong opioids in chronic non-cancer pain in adults. Evidence-based recommendations from the French Society for the study and treatment of pain","volume":"45","author":"Moisset","year":"2016","journal-title":"Presse Med"},{"issue":"2","key":"10.1016\/j.therap.2018.07.001_bib0400","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2515\/therapie\/2014221","article-title":"French Network of Centre for Evaluation and Information on Pharmacodependence (Addictovigilance Centres). Evaluation of abuse and dependence in addiction monitoring systems: tramadol as an example","volume":"70","author":"Roussin","year":"2015","journal-title":"Therapie"},{"issue":"3","key":"10.1016\/j.therap.2018.07.001_bib0405","article-title":"M\u00e9susage du fentanyl \u00e0 lib\u00e9ration imm\u00e9diate\u00a0: quand la d\u00e9pendance s\u2019installe","volume":"17","author":"Gibaja","year":"2015","journal-title":"Courr Addict"},{"key":"10.1016\/j.therap.2018.07.001_bib0410","series-title":"Enqu\u00eate officielle d\u2019addictovigilance des sp\u00e9cialit\u00e9s \u00e0 base d\u2019oxycodone","author":"ANSM","year":"2013"},{"issue":"5","key":"10.1016\/j.therap.2018.07.001_bib0415","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000346179","article-title":"Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France","volume":"19","author":"Peyriere","year":"2013","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2018.07.001_bib0420","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.therap.2016.11.002","article-title":"Quels sont les principaux faits marquants des 8\u00a0ans de suivi d\u2019addictovigilance de la m\u00e9thadone\u00a0?","volume":"72","author":"Frauger","year":"2017","journal-title":"Therapie"},{"issue":"5","key":"10.1016\/j.therap.2018.07.001_bib0425","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pharma.2009.06.005","article-title":"Mechanisms of opioid-induced overdose: experimental approach to clinical concerns","volume":"67","author":"Baud","year":"2009","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.therap.2018.07.001_bib0430","series-title":"Preventing fatal overdoses: a systematic review of the effectiveness of take-home naloxone","author":"EMCDDA European Monitoring Centre for Drugs and Drug Addiction","year":"2015"},{"issue":"8","key":"10.1016\/j.therap.2018.07.001_bib0435","first-page":"819","article-title":"Child poisonings with methadone in France: a 6-year prospective national survey since the availability of capsules in 2008","volume":"53","author":"Torrents","year":"2015","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.therap.2018.07.001_bib0440","doi-asserted-by":"crossref","first-page":"c5475","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database","volume":"341","author":"Cornish","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2018.07.001_bib0445","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2018.07.001_bib0450","series-title":"Preventing opioid overdose deaths with take-home naloxone","author":"EMCDDA European Monitoring Centre for Drugs and Drug Addiction","year":"2016"},{"issue":"5","key":"10.1016\/j.therap.2018.07.001_bib0455","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/add.13265","article-title":"Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006\u201310) versus after (2011\u201313) comparison","volume":"111","author":"Bird","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2018.07.001_bib0460","series-title":"Organisation mondiale de la sant\u00e9. Informations sur l\u2019overdose d\u2019opio\u00efdes","author":"OMS","year":"2014"},{"key":"10.1016\/j.therap.2018.07.001_bib0465","series-title":"Pr\u00e9venir les surdoses en opiac\u00e9s \u00e0 l\u2019aide de naloxone \u00e0 emporter \u00e0 domicile","author":"EMCDDA European Monitoring Centre for Drugs and Drug Addiction (communiqu\u00e9 de presse)","year":"2016"},{"issue":"4","key":"10.1016\/j.therap.2018.07.001_bib0470","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/03007995.2017.1334637","article-title":"Use of naloxone nasal spray 4mg in the community setting: a survey of use by community organizations","volume":"34","author":"Avetian","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.therap.2018.07.001_bib0475","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.annemergmed.2016.06.014","article-title":"Fentanyl and a novel synthetic opioid U-47700\u00a0masquerading as Street \u201cNorco\u201d in Central California: a case report","volume":"69","author":"Armenian","year":"2017","journal-title":"Ann Emerg Med"},{"issue":"7","key":"10.1016\/j.therap.2018.07.001_bib0480","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.drugpo.2015.04.003","article-title":"Fentanyls: are we missing the signs? Highly potent and on the rise in Europe","volume":"26","author":"Mounteney","year":"2015","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.therap.2018.07.001_bib0485","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.forsciint.2016.07.005","article-title":"Ocfentanil overdose fatality in the recreational drug scene","volume":"266","author":"Coopman","year":"2016","journal-title":"Forensic Sci Int"},{"issue":"9","key":"10.1016\/j.therap.2018.07.001_bib0490","first-page":"761","article-title":"An acute ocfentanil fatality: a case report with postmortem concentrations","volume":"40","author":"Dussy","year":"2016","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.therap.2018.07.001_bib0495","series-title":"D\u00e9c\u00e8s en relation avec l\u2019abus de m\u00e9dicaments et de substances\u00a0: principaux r\u00e9sultats enqu\u00eate DRAMES","author":"R\u00e9seau fran\u00e7ais d\u2019addictovigilance","year":"2015"},{"key":"10.1016\/j.therap.2018.07.001_bib0500","series-title":"D\u00e9c\u00e8s toxiques par antalgiques\u00a0: r\u00e9sultats","author":"R\u00e9seau fran\u00e7ais d\u2019addicovigilance","year":"2015"},{"key":"10.1016\/j.therap.2018.07.001_bib0505","series-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit Narcan\u00ae","author":"ANSM","year":"2012"},{"key":"10.1016\/j.therap.2018.07.001_bib0510","series-title":"Standards, options et recommandations\u00a0: traitements antalgiques m\u00e9dicamenteux des douleurs canc\u00e9reuses par exc\u00e8s de nociception chez l\u2019adulte","year":"2002"},{"key":"10.1016\/j.therap.2018.07.001_bib0515","series-title":"Standards, options et recommandations\u00a0: la morphine dans le cadre du changement d\u2019opioides ou de voie d\u2019administration chez l\u2019adulte avec une douleur due cancer","year":"2017"},{"key":"10.1016\/j.therap.2018.07.001_bib0520","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.drugpo.2016.08.004","article-title":"Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre","volume":"37","author":"Latimer","year":"2016","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.therap.2018.07.001_bib0525","unstructured":"Minist\u00e8re des affaires sociales, de la sant\u00e9. Arr\u00eat\u00e9 du 22\u00a0mars 2016\u00a0portant approbation du cahier des charges national relatif \u00e0 l\u2019exp\u00e9rimentation d\u2019espaces de r\u00e9duction des risques par usage supervis\u00e9, autrement appel\u00e9s \u00ab\u00a0salles de consommation \u00e0 moindre risque\u00a0\u00bb. https:\/\/www.legifrance.gouv.fr\/eli\/arrete\/2016\/3\/22\/AFSP1601434A\/jo. [Consult\u00e9 le 30\u00a0juin 2018]."},{"key":"10.1016\/j.therap.2018.07.001_bib0530","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.drugpo.2016.10.006","article-title":"The hidden web and the fentanyl problem: detection of ocfentanil as an adulterant in heroin","volume":"40","author":"Quintana","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"4","key":"10.1016\/j.therap.2018.07.001_bib0535","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1067\/mem.2002.128143","article-title":"Massive OxyContin ingestion refractory to naloxone therapy","volume":"40","author":"Schneir","year":"2002","journal-title":"Ann Emerg Med"},{"issue":"12","key":"10.1016\/j.therap.2018.07.001_bib0540","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.ajem.2017.05.033","article-title":"An increase in per-patient naloxone requirements in an opioid epidemic","volume":"35","author":"Birmingham","year":"2017","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.therap.2018.07.001_bib0545","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","article-title":"A review: fentanyl and non-pharmaceutical fentanyls","volume":"171","author":"Suzuki","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.therap.2018.07.001_bib0550","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/ADM.0000000000000324","article-title":"Misuse of novel synthetic opioids: a deadly new trend","volume":"11","author":"Prekupec","year":"2017","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2018.07.001_bib0555","series-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit Nalscue\u00ae","author":"ANSM","year":"2017"},{"issue":"3","key":"10.1016\/j.therap.2018.07.001_bib0560","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/ADM.0000000000000034","article-title":"systematic review of community opioid overdose prevention and naloxone distribution programs","volume":"8","author":"Clark","year":"2014","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2018.07.001_bib0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2017.04.021","article-title":"Heroin and pharmaceutical opioid overdose events: emergency medical response characteristics","volume":"178","author":"Banta-Green","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2018.07.001_bib0570","series-title":"Commission des stup\u00e9fiants et psychotropes du 12\u00a0f\u00e9vrier 2015","author":"ANSM","year":"2015"},{"key":"10.1016\/j.therap.2018.07.001_bib0575","series-title":"Commission des stup\u00e9fiants et psychotropes du 15\u00a0octobre 2015","author":"ANSM","year":"2015"},{"issue":"7","key":"10.1016\/j.therap.2018.07.001_bib0580","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/add.13326","article-title":"Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria","volume":"111","author":"McDonald","year":"2016","journal-title":"Addiction"},{"issue":"9912","key":"10.1016\/j.therap.2018.07.001_bib0585","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(14)60022-2","article-title":"Does take-home naloxone reduce non-fatal overdose?","volume":"383","author":"Benet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2018.07.001_bib0590","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2296-15-12","article-title":"Reducing drug related deaths: a pre-implementation assessment of knowledge, barriers and enablers for naloxone distribution through general practice","volume":"15","author":"Matheson","year":"2014","journal-title":"BMC Fam Pract"},{"issue":"1\u20132","key":"10.1016\/j.therap.2018.07.001_bib0595","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.drugalcdep.2013.02.007","article-title":"Development of opioid overdose knowledge (OOKS) and attitudes (OOAS) Scales for take-home naloxone training evaluation","volume":"132","author":"Williams","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2018.07.001_bib0600","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12954-016-0094-1","article-title":"Stakeholder perceptions and operational barriers in the training and distribution of take-home naloxone within prisons in England","volume":"13","author":"Sondhi","year":"2016","journal-title":"Harm Reduct J"},{"issue":"1","key":"10.1016\/j.therap.2018.07.001_bib0605","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1477-7517-11-33","article-title":"Coverage of overdose prevention programs for opiate users and injectors: a cross-sectional study","volume":"11","author":"Arribas-Ibar","year":"2014","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.therap.2018.07.001_bib0610","series-title":"European public assessment report for Nyxoid","author":"EMA","year":"2017"},{"key":"10.1016\/j.therap.2018.07.001_bib0615","series-title":"Naloxone adapt","author":"Heads of medicines agencies","year":"2017"},{"key":"10.1016\/j.therap.2018.07.001_bib0620","series-title":"Commission des stup\u00e9fiants et psychotropes du 12\u00a0janvier 2017","author":"ANSM","year":"2018"},{"key":"10.1016\/j.therap.2018.07.001_bib0625","series-title":"ATU Nalscue\u00ae","author":"ANSM","year":"2018"},{"key":"10.1016\/j.therap.2018.07.001_bib0630","unstructured":"ANSM. Point d\u2019information. Juillet 2016\u00a0: mise \u00e0 disposition d\u2019un spray nasal de naloxone aupr\u00e8s des usagers de drogues pour le traitement d\u2019urgence des surdoses aux opio\u00efdes. http:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Mise-a-disposition-d-un-spray-nasal-de-naloxone-aupres-des-usagers-de-drogues-pour-le-traitement-d-urgence-des-surdoses-aux-opioides-Point-d-information. [Consult\u00e9 le 30\u00a0juin 2018]."},{"key":"10.1016\/j.therap.2018.07.001_bib0635","series-title":"Point d\u2019information. Mise \u00e0 disposition \u00e9largie du spray nasal de naloxone (Nalscue)","author":"ANSM","year":"2016"},{"key":"10.1016\/j.therap.2018.07.001_bib0640","series-title":"Point d\u2019information\u00a0: spray nasal de naloxone (Nalscue)\u00a0: entr\u00e9e en vigueur de l\u2019AMM","author":"ANSM","year":"2018"},{"key":"10.1016\/j.therap.2018.07.001_bib0645","series-title":"Arr\u00eat\u00e9 du 13\u00a0octobre 2015\u00a0modifiant l\u2019arr\u00eat\u00e9 du 22\u00a0f\u00e9vrier 1990\u00a0portant exon\u00e9ration \u00e0 la r\u00e9glementation des substances v\u00e9n\u00e9neuses destin\u00e9es \u00e0 la m\u00e9decine humaine","author":"Minist\u00e8re des Affaires sociales, de la Sant\u00e9 et des Droits des femmes","year":"2015"},{"key":"10.1016\/j.therap.2018.07.001_bib0650","series-title":"R\u00e9sum\u00e9 du rapport de synth\u00e8se Nalscue\u00ae","author":"ANSM","year":"2018"},{"issue":"2","key":"10.1016\/j.therap.2018.07.001_bib0655","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2515\/therapie\/2015009","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.07.001_bib0330","unstructured":"R\u00e9seau fran\u00e7ais d\u2019addictovigilance. http:\/\/www.addictovigilance.fr\/. [Consult\u00e9 le 30\u00a0juin 2018]."}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718301197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718301197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T08:22:32Z","timestamp":1554279752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595718301197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0040595718301197"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.07.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}